Abstract:With the application of Mendelian randomization and co‐localization analysis methods, we found compelling indications for two proteins (LRP11 and ITIH1) and suggested indications for four proteins (PLCG1, ARHGAP25, CHGA, and MANBA), which might be promising targets for migraine treatment without obvious adverse consequences. Background Proteome‐wide Mendelian randomization studies have been increasingly utilized to identify potential drug targets for diseases. We aimed to identify potential therapeutic targets for migraine and its subtypes through the application of Mendelian randomization and co‐localization analysis methods. Methods We utilized cis‐protein quantitative trait loci data for 1378 plasma proteins available from two studies with 7213 individuals and 35,559 individuals, respectively. Summary data for migraine and its subtypes were obtained from a genetic study involving up to 1,339,303 individuals. Proteins that passed both the discovery and validation Mendelian randomization analysis, sensitivity analysis, heterogeneity test, and pleiotropy test, were associated with ≥2 outcomes, and received strong support from co‐localization analysis (PP.H4.abf ≥0.80) and were classified as tier 1 proteins. Results We identified three tier 1 proteins (LRP11, ITIH1, and ADGRF5), whose genes have not been previously identified as causal genes for migraine in genetic studies. LRP11 was significantly associated with the risk of any migraine (OR [odds ratio] = 0.968, 95% CI [confidence interval] = 0.955–0.981, p = 1.27 × 10−6) and significantly/suggestively associated with three migraine subtypes. ITIH1 was significantly associated with the risk of any migraine (OR = 1.044, 95% CI = 1.024–1.065, p = 1.08 × 10−5) and migraine with visual disturbances. ADGRF5 was significantly associated with the risk of any migraine (OR = 0.964, 95% CI = 0.946–0.982, p = 8.74 × 10−5) and suggestively associated with migraine with aura. The effects of LRP11 and ADGRF5 were further replicated using cerebrospinal fluid protein data. Apart from ADGRF5, there was no evidence of potential adverse consequences when modulating the plasma levels. We also identified another four proteins (PLCG1, ARHGAP25, CHGA, and MANBA) with no potential adverse consequences when modulating the plasma levels, and their genes were not reported by previous genetic studies. Conclusions We found compelling evidence for two proteins and suggestive evidence for four proteins that could be promising targets for migraine treatment without significant adverse consequences. The corresponding genes were not reported in previous genetic studies. Future studies are needed to confirm the causal role of these proteins and explore the underlying mechanisms.

Multi-omics Mendelian randomization integrating GWAS, eQTL and pQTL data revealed GSTM4 as a potential drug target for migraine

Proteome-wide Mendelian randomization identified potential drug targets for migraine

Identifying therapeutic target genes for migraine by systematic druggable genome-wide Mendelian randomization

MTHFR polymorphism's influence on the clinical features and therapeutic effects in patients with migraine: An observational study.

Comprehensive analysis of genetic associations and single-cell expression profiles reveals potential links between migraine and multiple diseases: a phenome-wide association study

Identifying novel proteins for migraine by integrating proteomes from blood and CSF with genome‐wide association data

Identifying Causal Genes for Migraine by Integrating the Proteome and Transcriptome.

Irritable Bowel Syndrome and Migraine: Evidence from Mendelian Randomization Analysis in the UK Biobank

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders

Association between TRP channels and glutamatergic synapse gene polymorphisms and migraine and the comorbidities anxiety and depression in a Chinese population

Integration of single-nucleus RNA sequencing and network disturbance to elucidate crosstalk between multicomponent drugs and trigeminal ganglia cells in migraine

Pharmacokinetics of the Material Basis Compounds of Tianshu Capsule in Treating Migraine

The 1400 metabolite-mediated relationship between 91 inflammatory cytokines and migraine: An exploratory two-step Mendelian randomization study

Multilocus analysis reveals three candidate genes for Chinese migraine susceptibility.

Identification of genetic susceptibility for Chinese migraine with depression using machine learning

Identification of drug targets for Sjögren's syndrome: multi-omics Mendelian randomization and colocalization analyses

Metabolomics integrated with mass spectrometry imaging reveals novel action of tetramethylpyrazine in migraine

Multi-omics integration prioritizes potential drug targets for multiple sclerosis

To analyze the relationship between gut microbiota, metabolites and migraine: a two-sample Mendelian randomization study

Causal relationships between migraine and microstructural white matter: a Mendelian randomization study

Causality between migraine and cardiovascular disease: a bidirectional Mendelian randomization study